KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.

Mohamed A Kamal, Matthew P Kosloski, Ching-Ha Lai, Michael A Partridge, Manoj Rajadhyaksha, Vanaja Kanamaluru, Ashish Bansal, Arsalan Shabbir, Brad Shumel, Marius Ardeleanu, Susan M Richards, Hong Yan, Christine R Xu, Ainara Rodríguez-Marco, Jing Xiao, Faisal A Khokhar, Guy Gherardi, Elisa Babilonia, Jennifer Maloney, Eric Mortensen, Bolanle Akinlade, Ned Braunstein, Neil Stahl, Albert Torri, John D Davis, A Thomas DiCioccio

Front Immunol 15 1466372

PMID39588375
PMCIDPMC11586717
DOI10.3389/fimmu.2024.1466372
发表日期2024-11-26
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Development of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) to monoclonal antibodies may adversely impact pharmacokinetics, efficacy, and/or safety. OBJECTIVE: To describe incidence, titer, and persistence of dupilumab ADAs and NAbs, and their effects on pharmacokinetics, efficacy, and safety in patients with atopic dermatitis (AD). METHODS: This analysis included seven phase 3 randomized, placebo-controlled (N=2,992) and two long-term open-label extension (N=2,287) trials of subcutaneous dupilumab in adults and pediatric patients with moderate-to-severe AD. ADA, NAb, and dupilumab concentration in serum were assessed using validated immunoassays. ADA impacts on efficacy (EASI) and safety were assessed. RESULTS: Treatment-emergent ADAs were observed in up to 8.6% (aged ≥18 years), 16.0% (12-17 years), 5.3% (6-11 years), and 2.0% (6 months to 5 years) dupilumab-treated patients. Among dupilumab-treated patients, ≤3.7% had persistent responses, <1% had high titers (≥10,000), and ≤5.1% were NAb-positive. NAbs were more common in patients with moderate- and high-titer ADA responses. High-titer ADAs, while infrequent, were the variable most associated with lower dupilumab concentrations in serum and loss of efficacy, independent of NAb status. Efficacy was generally similar in ADA-positive and -negative patients. For most patients with high- or moderate-titer ADAs, titers decreased and efficacy improved over time with continued dupilumab treatment. ADA-positive and -negative patients had similar incidences of treatment-emergent and serious treatment-emergent adverse events. One patient with high-titer ADAs developed serum sickness. CONCLUSION: In patients with AD, ADAs and NAbs had minimal impact on dupilumab concentration, efficacy, and safety, except for high-titer ADAs in a small number of patients. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifiers (NCT02277743, NCT02277769, NCT02260986, NCT02395133, NCT01949311, NCT03054428, NCT03345914, NCT02612454, and NCT03346434).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。